

#

**Contents**

	<b>Page</b>
<b>1. INTRODUCTION.....</b>	<b>1</b>
1.1 Biological context and scope of this thesis.....	3
1.2 The urea cycle and the consequences of its derangements...	5
1.3 Biological significance of CPS1 and of its allosteric regulation by NAG.....	9
1.4 A brief review of knowledge about CPS1 that is relevant for this work.....	12
1.4.1 <i>Early findings</i> .....	12
1.4.2 <i>Initial work with pure CPSs</i> .....	13
1.4.3 <i>Reactional mechanism</i> .....	14
1.4.4 <i>Human CPS1</i> .....	15
1.4.5 <i>NAG activation and domain structure</i> .....	15
1.4.6 <i>Cloning and sequencing of CPS1 cDNA                 and gross enzyme architecture</i> .....	16
1.4.7 <i>Crystal structure of E. coli CPS</i> .....	17
1.4.8 <i>Crystallographic data on the structure of                 the C-terminal domain of human CPS1, and                 NAG site delineation</i> .....	19
1.4.9 <i>Modelling of the CPS1 structure</i> .....	20
1.4.10 <i>CPS1 production</i> .....	21
1.5 CPS1 deficiency, the CPS1 gene and its mutations.....	22
1.6 Other roles of CPS1 in pathology.....	26
1.6.1 <i>Secondary hyperammonemia</i> .....	26
1.6.2 <i>A CPS1 polymorphism involved in vascular                 reactivity and in other traits related to                 pathologies</i> .....	27

#

# CONTENTS

#

	<b>Page</b>
1.7 Previous in vitro expression and structure-function studies on CPSs.....	29
1.8 The baculovirus/insect cell expression system.....	31
1.9 Site-directed mutagenesis.....	38
1.10 CPS1 activity assays.....	41
1.11 Study goals, contents, involved laboratories, and role of myself.....	44
<b>2. RESULTS .....</b>	<b>47</b>
<b>2.1 Results. Chapter 1.....</b>	<b>49</b>
2.1.1 <i>Abstract</i> .....	50
2.1.2 <i>Introduction</i> .....	51
2.1.3 <i>Patients and Methods</i> .....	54
2.1.3.1 Patients and CPS1 mutations.....	54
2.1.3.2 Recombinant human CPS1 production..	54
2.1.3.3 Enzyme purification.....	57
2.1.3.4 Enzyme activity assays.....	58
2.1.3.5 Other techniques.....	58
2.1.4 <i>Results and Discussion</i> .....	60
2.1.4.1 Producing human CPS1 in a baculo-virus/insect cell system.....	60
2.1.4.2 Recombinant human CPS1 represents well the natural liver enzyme.....	61
2.1.4.3 Glycerol partially replaces NAG in the activation of human CPS1.....	62

#

#

	<b>Page</b>
2.1.4.4 Limited proteolysis reveals the hCPS1 domain organization.....	62
2.1.4.5 Testing the effects of clinical CPS1D mutations on enzyme functionality.....	64
2.1.4.6 Influence of the substrates and of NAG on the resistance of human CPS1 to proteolytic or thermal inactivation.....	68
2.1.4.7 Final comments.....	69
2.1.5 <i>Acknowledgements and Disclosure statement</i> .....	74
2.1.6 <i>References</i> .....	74
<b>2.2 Results. Chapter 2</b> .....	<b>79</b>
2.2.1 <i>Abstract and key words</i> .....	80
2.2.2 <i>Introduction</i> .....	81
2.2.3 <i>Materials and Methods</i> .....	85
2.2.3.1 Patients and CPS1 Mutations.....	85
2.2.3.2 Production of CPS1 carrying the desired mutations.....	85
2.2.3.3 Enzyme activity assays.....	87
2.2.3.4 Other assays.....	87
2.2.4 <i>Results</i> .....	89
2.2.4.1 CPS1D mutations that affect the UFSD	89
2.2.4.2 UFSD mutations negatively influence the yield of CPS1.....	90
2.2.4.3 Eight UFSD mutations strongly impair CPS1 activity.....	92
2.2.4.4 Activity and stability changes with an- other eight UFSD mutations.....	92

#

# CONTENTS

#

	<b>Page</b>
2.2.4.5 $K_m$ effects are the major changes associated with mutations affecting Arg850.....	95
2.2.4.6 UFSD mutations generally decrease $V_{max}$ of the enzyme.....	97
2.2.5 <i>Discussion</i> .....	98
2.2.6 <i>Supplementary material: Structural rationalization of the mutations effects</i> .....	100
2.2.7 <i>Acknowledgements/conflict of interest statement</i>	103
2.2.8 <i>References</i> .....	103
<b>2.3 Results. Chapter 3</b> .....	<b>109</b>
2.3.1 <i>Abstract and key words</i> .....	110
2.3.2 <i>Introduction</i> .....	111
2.3.3 <i>Results</i> .....	114
2.3.3.1 Clinical ASD domain mutations studied	114
2.3.3.2 Impact of the clinical mutations on enzyme stability.....	114
2.3.3.3 Effects of clinical ASD mutations on CPS1 activity and on the kinetic parameters for NAG.....	115
2.3.3.4 The effects of ASD mutations shed further light on signal transmission and NAG binding.....	119
2.3.3.5 Modeling of the NAG site.....	121
2.3.4 <i>Discussion</i> .....	122
2.3.5 <i>Materials and Methods</i> .....	126
2.3.5.1 Human CPS1 production.....	126
2.3.5.2 CPS1 activity assays.....	127

## VIII

#

## CONTENTS

#

	<b>Page</b>
2.3.5.3 Restrained molecular dynamics (MD) and docking calculations.....	127
2.3.5.4 Other techniques.....	128
2.3.6 <i>Acknowledgements</i> .....	129
2.3.7 <i>References</i> .....	129
<b>3. DISCUSSION.....</b>	<b>135</b>
<b>4. CONCLUSIONS.....</b>	<b>149</b>
<b>5. REFERENCES.....</b>	<b>153</b>

#

# CONTENTS

#

#

X

#